Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 13 min ago
Peer-reviewedCC BY-NC 4.0International Journal of Immunopathology and Pharmacology

Atypical cytokine release syndrome induced by carboplatin: The first described case report

  • Maria Cruz Torres Górriz1,2,3
  • Julian Borrás Cuartero4
  • Anna Bosh Requena5
  • Dah Tay Jang1
  • Ernesto Enrique1,2,3
5 affiliations
  1. 1Allergy Department, General University Hospital of Castellón, Castellón, Spain
  2. 2Doctoral School, Jaume I University, Castellon de la Plana, Spain
  3. 3FISABIO Foundation Research Group, Valencia, Spain
  4. 4Allergy Department, Castellon Provincial Hospital Consortium, Castellón, Spain
  5. 5Allergy Department, University Clinical Hospital of Valencia, Valencia, Spain
Read full textDOICite

Abstract

Introduction: Hypersensitivity reactions to carboplatin include type I reactions, mixed reactions, and delayed reactions.

Case report: We report a case of an atypical cytokine release syndrome induced by carboplatin in a patient with breast carcinoma.

Management & outcome: The patient developed clinical manifestations consisting of a delayed cytokine release syndrome following administration of carboplatin and paclitaxel. To establish the diagnosis, she underwent a double desensitization protocol over two consecutive days with paclitaxel and carboplatin. A delayed elevation of interleukin-6 after carboplatin supported the diagnosis of an isolated cytokine release syndrome. The patient subsequently continued treatment with paclitaxel through standard infusions and with carboplatin using a desensitization protocol.

Discussion: Cytokine release syndrome associated with carboplatin has been previously reported as occurring immediately after infusion and as part of a mixed phenotype (type I and cytokine release). A delayed-onset cytokine release syndrome induced by carboplatin, occurring outside the context of a mixed reaction, is reported.

Conclusion: Cytokine release syndrome may present as an isolated, delayed reaction following carboplatin infusion. Measurement of interleukin-6 may be a valuable diagnostic tool for confirming the diagnosis of cytokine release syndrome.

Related

  1. Long-Term Cardiovascular Care After Cytokine Release Syndrome
    Belén Terol, Ana Martín-García, Dimitrios Farmakis +4
    JACC: CardioOncologyPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicinePMCEurope PMC
  2. Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell–Associated Neurotoxicity Syndrome
    Stanley Kim, Fred Schiffman, Matthew Hadfield +6
    Journal of Brown hospital medicinePeer-reviewedCC BY-NCFull textOncologyEurope PMCPMC
  3. INTEGRATED IMMUNOPHENOTYPING REVEALS DISTINCT MULTICOMPARTMENT IMMUNE SIGNATURES ASSOCIATED WITH CYTOKINE RELEASE SYNDROME FOLLOWING ANTI-CD19 CAR-T CELL THERAPY
    Mariana Soares GOMES, Arianne Fagotti GUSMãO, Larissa Campos SOUZA +15
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textOncologyDOAJ
  4. The Diverse Clinical Spectrum of Noonan Syndrome in Pediatric Endocrinology: From Classical to Atypical Phenotypes
    Sara Aszkiełowicz, Anna Łupińska, Arkadiusz Zygmunt +1
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. A rare case report: atypical presentation of Klinefelter syndrome in a 24-year-old male at suburban tertiary care hospital in Nepal
    Annals of medicine and surgery (2012)Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{gorriz2026atypical,
  title = {{Atypical cytokine release syndrome induced by carboplatin: The first described case report}},
  author = {Maria Cruz Torres Górriz and Julian Borrás Cuartero and Anna Bosh Requena and Dah Tay Jang and Ernesto Enrique},
  journal = {International Journal of Immunopathology and Pharmacology},
  year = {2026},
  month = sep,
  doi = {10.1177/03946320261472669},
  url = {https://doi.org/10.1177/03946320261472669},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Atypical cytokine release syndrome induced by carboplatin: The first described case report
AU  - Maria Cruz Torres Górriz
AU  - Julian Borrás Cuartero
AU  - Anna Bosh Requena
AU  - Dah Tay Jang
AU  - Ernesto Enrique
PY  - 2026
DA  - 2026/09/21
JO  - International Journal of Immunopathology and Pharmacology
DO  - 10.1177/03946320261472669
UR  - https://doi.org/10.1177/03946320261472669
AB  - Introduction: Hypersensitivity reactions to carboplatin include type I reactions, mixed reactions, and delayed reactions.  Case report: We report a case of an atypical cytokine release syndrome induced by carboplatin in a patient with breast carcinoma.  Management & outcome: The patient developed clinical manifestations consisting of a delayed cytokine release syndrome following administration of carboplatin and paclitaxel. To establish the diagnosis, she underwent a double desensitization protocol over two consecutive days with paclitaxel and carboplatin. A delayed elevation of interleukin-6 after carboplatin supported the diagnosis of an isolated cytokine release syndrome. The patient subsequently continued treatment with paclitaxel through standard infusions and with carboplatin using a desensitization protocol.  Discussion: Cytokine release syndrome associated with carboplatin has been previously reported as occurring immediately after infusion and as part of a mixed phenotype (type I and cytokine release). A delayed-onset cytokine release syndrome induced by carboplatin, occurring outside the context of a mixed reaction, is reported.  Conclusion: Cytokine release syndrome may present as an isolated, delayed reaction following carboplatin infusion. Measurement of interleukin-6 may be a valuable diagnostic tool for confirming the diagnosis of cytokine release syndrome.
SN  - 0394-6320
SN  - 2058-7384
ER  -